Eikon Therapeutics

Clinical-stage biotech combining engineering with molecular and cell biology to speed up drug discovery and development; listed on Nasdaq in 2026.

View on the globe

$732MEquity raised in 2025–20262025 $351M · 2026 $381M · 2 equity rounds
$732MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from 26 Feb 2025 to 4 Feb 2026, $732M equity disclosed. Earlier rounds exist but are not sourced.26 Feb 2025: Series D (initial closing), $351M; 4 Feb 2026: Initial public offering (Nasdaq: EIKN), $381M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 20192025Q2Q3Q42026Q2Equity round4 Feb 2026 · Initial public offering (Nasdaq: EIKN) · $381M26 Feb 2025 · Series D (initial closing) · $351MIPO · $381MSeries D · $351M
Funding history: 2 rounds from 26 Feb 2025 to 4 Feb 2026, $732M equity disclosed. Earlier rounds exist but are not sourced.26 Feb 2025: Series D (initial closing), $351M; 4 Feb 2026: Initial public offering (Nasdaq: EIKN), $381M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’19Q2Q3Q42026Q2Equity round4 Feb 2026 · Initial public offering (Nasdaq: EIKN) · $381M26 Feb 2025 · Series D (initial closing) · $351M$381M$351M

Funding history 2 rounds · 2 sources · newest first

Earlier rounds not yet sourced. Eikon Therapeutics was founded in 2019 and raised before 26 Feb 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Initial public offering (Nasdaq: EIKN)
    Amount$381M
    Post-money—
    ✓ Confirmed
    Note
    21,177,600 shares at $18.00, gross proceeds about $381M before the underwriters' option; excluded from private venture totals as an IPO.
    Sources
  2. Series D (initial closing)
    Amount$351M
    Post-money—
    ✓ Confirmed
    Also
    Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, T. Rowe Price, UC Investments
    Note
    Led by existing investors (no single lead named); announced as an initial closing. Company states more than $1.1B raised privately since founding; earlier rounds not sourced here.
    Sources
  3. Earlier rounds not yet sourced

Investors 11

  • Alexandria Venture Investments
  • AME Cloud Ventures
  • E15 VC
  • Foresite Capital
  • General Catalyst
  • Lux Capital
  • Soros Capital
  • StepStone Group
  • T. Rowe Price
  • The Column Group
  • UC Investments

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Eikon Therapeutics and its logo are trademarks of their owners, used here for identification only.